Consultant Profile

Dr James Rosengarten MBBS DM MRCP

Practising at: Ashford and Margate

Specialties: Palpitations, Arrhythmia, Irregular Heart Rhythm, AF, Atrial Fibrillation, Atrial Flutter, SVT, AVNRT, WPW, PoTS, SCD, Sudden Cardiac Death, Defibrillators, Cardiology

Special clinical interests: In addition to the common problems of chest pain and breathlessness, as a cardiac electrophysiologist Dr Rosengarten has a particular interest in patients with irregular heartbeats, palpitations, SVT, atrial flutter, fibrillation, and tachycardia. He is the only cardiologist in the region who offers curative ablation for these procedures.

He also manages patients who need heart monitors, pacemakers, ICDs and defibrillators. He has developed the East Kent programme for His bundle and physiological pacemakers, and subcutaneous ICD implantation.

Current NHS and /or university posts: Clinical Lead for Arrhythmia
East Kent Hospitals University NHS Foundation Trust
Barts Health NHS Trust

Year of first medical qualification and medical school attended: 2002, University of London

Current membership(s) of professional, national and regional bodies: British Heart Rhythm Society
British Cardiovascular Society

Background Information

For online bookings please visit the consultant's website.

Dr Rosengarten is a cardiologist with particular interest and expertise in cardiac rhythm management. He is passionate about delivering accessible healthcare, meeting the demands of the local population in East Kent and addressing the unmet needs of those suffering with highly symptomatic rhythm disturbance and patients at risk of lethal arrhythmia across the wider region.

His training has included many aspects of electrophysiology including diagnosis and catheter ablation of AV nodal and pathway mediated tachycardias, atrial fibrillation and ventricular tachycardia. He manages pacemakers and defibrillators, including implantation, follow-up, and troubleshooting, including extraction.

Dr Rosengarten's research experience is in the use of novel risk stratification tools for sudden cardiac death, utilising biomedical engineering techniques, including artificial intelligence and machine learning, to identify serum protein, imaging and electrocardiographic biomarkers.